We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Sexual Health · 5 min read

Vaginal dryness and GSM: the symptom no one wants to talk about

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published · Updated

Genitourinary syndrome of menopause is common, progressive, and highly treatable.

GSM affects more than half of postmenopausal women and worsens over time without treatment. Symptoms include vaginal dryness, painful intercourse, urinary urgency, and recurrent UTIs.

What works

  • Low-dose vaginal estrogen — extremely safe and highly effective for most patients, including many breast cancer survivors after oncology coordination
  • Vaginal hyaluronic acid suppositories
  • Ospemifene (a SERM) for those who cannot use vaginal estrogen
  • Regular sexual activity (with or without a partner) preserves tissue elasticity

GSM rarely improves on its own. Earlier treatment is easier and more effective than waiting.

Sources

Medically reviewed by Kindr Health Clinical Team
Last updated: May 10, 2026

More on libido & sexual health

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Keep reading

Research

Hot flashes and your relationship: what partners miss, and how to start the treatment conversation

In a U.S. survey of 253 couples, 78.7% of the women, all with bothersome hot flashes, said they had never been treated for them. Here's what partners often miss, a visit-prep script, and hormonal and nonhormonal options to discuss.

Research

FDA requires GLP-1 label updates for a potential NAION eye risk: what it means

FDA is requiring GLP-1 label updates for a potential increased risk of NAION—sudden, painless vision loss in one eye. Here's what patients should know.

Research

Non-Hormonal Hot Flash Treatment: Lynkuet vs Veozah

Veozah and Lynkuet are two newer FDA-approved nonhormonal options for hot flashes. How they differ, key risks, and what to ask your clinician. Educational only.

Explore your next step

Kindr Care is being updated, and the exact clinical process will depend on the current care pathway.

Explore care options →